Hemostatic Agents Market

Hemostatic Agents Market (Product Type: Active Agents, Passive Agents, and Combination) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Hemostatic Agents Market Outlook 2031

  • The industry was valued at US$ 2.6 Bn in 2022
  • It is estimated to grow at a CAGR of 6.2% from 2023 to 2031 and reach US$ 4.5 Bn by the end of 2031

Analyst Viewpoint

Increase in cases of road accidents and rise in prevalence of chronic diseases are driving the hemostatic agents market trajectory. Hemostatic materials are prepared in various forms for wound care applications based on the active ingredients used.

Rise in number surgeries and surge in adoption of minimally invasive surgeries are also fueling the hemostatic agents industry expansion.

Key players are introducing cutting-edge solutions that improve the precision, effectiveness, and accessibility of hemostasis agents.

They are also developing hemostatic medical devices utilizing proprietary gel technologies. Vendors are offering advanced hemostatic agents for surgical applications in human and animal health sectors.

Market Introduction

Hemostasis is a process that stops bleeding or blood flow through a blood vessel, or hemorrhage. Hemostasis is a process by which a clot is formed in the injured area, thereby repairing the blood vessels.

Hemostatic agents are utilized to stem blood flow via the increased promotion of clotting, thereby improving the hemostasis by accelerating the coagulation process.

Hemostatic agents play a vital role in the treatment or prevention of bleeding, thereby indicating their usage in various therapeutic areas.

Attribute Detail
Drivers
  • Increase in Cases of Road Accidents
  • Rise in Prevalence of Chronic Diseases

Increase in Cases of Road Accidents Augmenting Hemostatic Agents Market Development

Hemostasis agents are mainly utilized to reduce blood flow via the increased promotion of clotting. By improving the body's normal clotting process, these medication minimizes the chance of severe blood loss and enhance patients' condition. These are important in emergency medical scenarios where treating the injury or stopping bleeding is crucial.

Increase in number of road accidents is anticipated to spur the hemostatic agents market growth in the near future.

According to a report published by the Government of India, a total of 461,312 road accidents occurred in the country as per official records. Road accidents often require emergency treatments due to serious injuries.

Surge in number of surgeries and improved access to healthcare facilities are driving the hemostatic agents market value. In 2020, a study published in the International Journal of Surgery reported that 310 million major procedures are performed globally each year, with 20 million in Europe and 40 to 50 million in the U.S.

Rise in Prevalence of Chronic Diseases Boosting Market Demand

The International Society on Thrombosis and Hemostasis 2022 report stated that there are roughly 10 million cases of venous thromboembolism globally each year. The same source states that 544,000 deaths in Europe each year are attributed to deep vein thrombosis (DVT).

According to the 2022 Report: Disorders of The Blood, over 3.2 million people in the U.S. suffer from a bleeding disorder every year. Thus, rise in number of patients with blood disorders is fueling the market revenue.

Increase in geriatric population is also augmenting the demand for hemostasis agents as the aging population is more likely to develop chronic illnesses and need various types of surgeries.

Regional Outlook

Attribute Detail
Leading Region North America

According to the latest hemostatic agents market analysis, North America held largest share in 2022. Presence of key players and rise in number of surgical procedures are propelling the market dynamics of the region. Surge in funding for clinical research and development by public and private organizations is also contributing to the hemostatic agents industry share in North America.

According to the U.S. Census Bureau, the number of senior people residing in the U.S. in 2021 was over 55 million, representing 17.1% of the overall population. By 2050, the percentage of adults in the country who are 65 years of age or older is expected to increase to around 22% of the total population.

Thus, growth in elderly population is projected to boost the demand for minimally invasive surgical procedures, thereby augmenting the hemostatic agents market size in North America.

Analysis of Key Players

Key players operating in the global hemostatic agents market are concentrating on providing a wide range of options for treating excessive blood flow during severe injuries or surgeries.

They are also introducing cutting-edge solutions that improve the precision, effectiveness, and accessibility of hemostatic agents, as well as forging strategic alliances and growing their global footprint.

Baxter, Ethicon, Inc., BD, B. Braun SE, Pfizer, Inc., Teleflex Incorporated, CryoLife, Inc., Integra LifeScience, Advanced Medical Solutions Group plc, and GELITA AG are some of the key players in the hemostatic agents market.

These companies have been profiled in the hemostatic agents market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.

Key Developments

  • In July 2023, Baxter International Inc. launched the PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
  • In 2022, Cresilon, Inc., a biotechnology company developing and manufacturing innovative hemostatic medical device technologies, announced the successful completion of a US$ 25 Mn Series A-4 financing round. The financing will support the company's efforts to aggressively accelerate its global expansion plan and bring its revolutionary hemostatic gel to the human health market.

Hemostatic Agents Market Snapshot

Attribute Detail
Market Size in 2022 US$ 2.6 Bn
Market Forecast (Value) in 2031 US$ 4.5 Bn
Growth Rate (CAGR) 6.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product Type
    • Active Agents
    • Passive Agents
    • Combination
  • Specialty / Therapeutic Area
    • Cardiology
    • Cath Lab
    • Trauma
    • General Surgery
    • ObGyn
    • Transplant
    • Oncology
    • Neurology
    • Orthopedic
    • Plastic Surgery
    • Dental
    • Others (Urological Surgeries, Pulmonary Surgeries)
  • Distribution Channel
    • Large Hospital (500+ Beds)
    • Medium Hospital (250-499 Beds)
    • Small Hospitals (Less than 250 Beds)
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries
Companies Profiled
  • Baxter
  • Ethicon, Inc.
  • BD
  • B. Braun SE
  • Pfizer, Inc.
  • Teleflex Incorporated
  • CryoLife, Inc.
  • Integra LifeSciences
  • Advanced Medical Solutions Group plc
  • GELITA AG
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global hemostatic agents market in 2022?

It was valued at US$ 2.6 Bn in 2022

How is the hemostatic agents industry expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 6.2% from 2023 to 2031

What are the key factors driving the demand for hemostatic agents?

Increase in cases of road accidents and rise in prevalence of chronic diseases

Which was the major region in the global hemostatic agents landscape in 2022?

North America was the leading region in 2022

Who are the prominent hemostatic agent manufacturers?

Baxter, Ethicon, Inc., BD, B. Braun SE, Pfizer, Inc., Teleflex Incorporated, CryoLife, Inc., Integra LifeScience, Advanced Medical Solutions Group plc, and GELITA AG

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemostatic Agents Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Hemostatic Agents Market Analysis and Forecast, 2017-2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product/Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Hemostatic Agents Market Analysis and Forecast, by Product Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Product Type, 2017-2031

        6.3.1. Active Agents

        6.3.2. Passive Agents

        6.3.3. Combination

    6.4. Market Attractiveness Analysis, by Product Type

7. Global Hemostatic Agents Market Analysis and Forecast, by Specialty / Therapeutic Area

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031

        7.3.1. Cardiology

        7.3.2. Cath Lab

        7.3.3. Trauma

        7.3.4. General Surgery

        7.3.5. ObGyn

        7.3.6. Transplant

        7.3.7. Oncology

        7.3.8. Neurology

        7.3.9. Orthopedic

        7.3.10. Plastic Surgery

        7.3.11. Dental

        7.3.12. Others

    7.4. Market Attractiveness Analysis, by Specialty / Therapeutic Area

8. Global Hemostatic Agents Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017-2031

        8.3.1. Large Hospital (500+ Beds)

        8.3.2. Medium Hospital (250-499 Beds)

        8.3.3. Small Hospitals (Less than 250 Beds)

    8.4. Market Attractiveness Analysis, by Specialty / Therapeutic Area

9. Global Hemostatic Agents Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017-2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Hemostatic Agents Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Product Type, 2017-2031

        10.3.1. Active Agents

        10.3.2. Passive Agents

        10.3.3. Combination

    10.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031

        10.4.1. Cardiology

        10.4.2. Cath Lab

        10.4.3. Trauma

        10.4.4. General Surgery

        10.4.5. ObGyn

        10.4.6. Transplant

        10.4.7. Oncology

        10.4.8. Neurology

        10.4.9. Orthopedic

        10.4.10. Plastic Surgery

        10.4.11. Dental

        10.4.12. Others

    10.5. Market Value Forecast, by Distribution Channel, 2017-2031

        10.5.1. Large Hospital (500+ Beds)

        10.5.2. Medium Hospital (250-499 Beds)

        10.5.3. Small Hospitals (Less than 250 Beds)

    10.6. Market Value Forecast, by Country, 2017-2031

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Product Type

        10.7.2. By Specialty / Therapeutic Area

        10.7.3. By Distribution Channel

        10.7.4. By Country

11. Europe Hemostatic Agents Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Product Type, 2017-2031

        11.3.1. Active Agents

        11.3.2. Passive Agents

        11.3.3. Combination

    11.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031

        11.4.1. Cardiology

        11.4.2. Cath Lab

        11.4.3. Trauma

        11.4.4. General Surgery

        11.4.5. ObGyn

        11.4.6. Transplant

        11.4.7. Oncology

        11.4.8. Neurology

        11.4.9. Orthopedic

        11.4.10. Plastic Surgery

        11.4.11. Dental

        11.4.12. Others

    11.5. Market Value Forecast, by Distribution Channel, 2017-2031

        11.5.1. Large Hospital (500+ Beds)

        11.5.2. Medium Hospital (250-499 Beds)

        11.5.3. Small Hospitals (Less than 250 Beds)

    11.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Product Type

        11.7.2. By Specialty / Therapeutic Area

        11.7.3. By Distribution Channel

        11.7.4. By Country/Sub-region

12. Asia Pacific Hemostatic Agents Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Product Type, 2017-2031

        12.3.1. Active Agents

        12.3.2. Passive Agents

        12.3.3. Combination

    12.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031

        12.4.1. Cardiology

        12.4.2. Cath Lab

        12.4.3. Trauma

        12.4.4. General Surgery

        12.4.5. ObGyn

        12.4.6. Transplant

        12.4.7. Oncology

        12.4.8. Neurology

        12.4.9. Orthopedic

        12.4.10. Plastic Surgery

        12.4.11. Dental

        12.4.12. Others

    12.5. Market Value Forecast, by Distribution Channel, 2017-2031

        12.5.1. Large Hospital (500+ Beds)

        12.5.2. Medium Hospital (250-499 Beds)

        12.5.3. Small Hospitals (Less than 250 Beds)

    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        12.6.1. China

        12.6.2. Japan

        12.6.3. India

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis

        12.7.1. By Product Type

        12.7.2. By Specialty / Therapeutic Area

        12.7.3. By Distribution Channel

        12.7.4. By Country/Sub-region

13. Latin America Hemostatic Agents Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Product Type, 2017-2031

        13.3.1. Active Agents

        13.3.2. Passive Agents

        13.3.3. Combination

    13.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031

        13.4.1. Cardiology

        13.4.2. Cath Lab

        13.4.3. Trauma

        13.4.4. General Surgery

        13.4.5. ObGyn

        13.4.6. Transplant

        13.4.7. Oncology

        13.4.8. Neurology

        13.4.9. Orthopedic

        13.4.10. Plastic Surgery

        13.4.11. Dental

        13.4.12. Others

    13.5. Market Value Forecast, by Distribution Channel, 2017-2031

        13.5.1. Large Hospital (500+ Beds)

        13.5.2. Medium Hospital (250-499 Beds)

        13.5.3. Small Hospitals (Less than 250 Beds)

    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Product Type

        13.7.2. By Specialty / Therapeutic Area

        13.7.3. By Distribution Channel

        13.7.4. By Country/Sub-region

14. Middle East & Africa Hemostatic Agents Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, by Product Type, 2017-2031

        14.3.1. Active Agents

        14.3.2. Passive Agents

        14.3.3. Combination

    14.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031

        14.4.1. Cardiology

        14.4.2. Cath Lab

        14.4.3. Trauma

        14.4.4. General Surgery

        14.4.5. ObGyn

        14.4.6. Transplant

        14.4.7. Oncology

        14.4.8. Neurology

        14.4.9. Orthopedic

        14.4.10. Plastic Surgery

        14.4.11. Dental

        14.4.12. Others

    14.5. Market Value Forecast, by Distribution Channel, 2017-2031

        14.5.1. Large Hospital (500+ Beds)

        14.5.2. Medium Hospital (250-499 Beds)

        14.5.3. Small Hospitals (Less than 250 Beds)

    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Product Type

        14.7.2. By Specialty / Therapeutic Area

        14.7.3. By Distribution Channel

        14.7.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2022)

    15.3. Company Profiles

        15.3.1. Baxter

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Ethicon, Inc.

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. BD

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. B. Braun SE

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Pfizer, Inc.

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Teleflex Incorporated

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. CryoLife, Inc.

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Integra LifeSciences

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Advanced Medical Solutions Group plc

            15.3.9.1. Company Overview

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. GELITA AG

            15.3.10.1. Company Overview

            15.3.10.2. Product Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

Table 02: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031

Table 03: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 04: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Region, 2017-2031

Table 05: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Country, 2017-2031

Table 06: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

Table 07: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031

Table 08: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 09: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 10: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

Table 11: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031

Table 12: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 13: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 14: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

Table 15: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031

Table 16: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 17: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

Table 19: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031

Table 20: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 21: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031

Table 23: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031

Table 24: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Hemostatic Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031

Figure 02: Global Hemostatic Agents Market Revenue (US$ Mn), by Product Type, 2022

Figure 03: Global Hemostatic Agents Market Value Share, by Product Type, 2022

Figure 04: Global Hemostatic Agents Market Revenue (US$ Mn), by Specialty / Therapeutic Area, 2022

Figure 05: Global Hemostatic Agents Market Value Share, by Specialty / Therapeutic Area, 2022

Figure 06: Global Hemostatic Agents Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Hemostatic Agents Market Value Share, by Distribution Channel, 2022

Figure 08: Global Hemostatic Agents Market Value Share, by Region, 2022

Figure 09: Global Hemostatic Agents Market Value (US$ Mn) Forecast, 2017-2031

Figure 10: Global Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031

Figure 11: Global Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 12: Global Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031

Figure 13: Global Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031

Figure 14: Global Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031

Figure 15: Global Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 16: Global Hemostatic Agents Market Value Share Analysis, by Region, 2022-2031

Figure 17: Global Hemostatic Agents Market Attractiveness Analysis, by Region, 2023-2031

Figure 18: North America Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 19: North America Hemostatic Agents Market Attractiveness Analysis, by Country, 2023-2031

Figure 20: North America Hemostatic Agents Market Value Share Analysis, by Country, 2022-2031

Figure 21: North America Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031

Figure 22: North America Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031

Figure 23: North America Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031

Figure 24: North America Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 25: North America Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031

Figure 26: North America Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 27: Europe Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 28: Europe Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 29: Europe Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 30: Europe Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031

Figure 31: Europe Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031

Figure 32: Europe Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031

Figure 33: Europe Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 34: Europe Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031

Figure 35: Europe Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 36: Asia Pacific Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 37: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 38: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 39: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031

Figure 40: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031

Figure 41: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031

Figure 42: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 43: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031

Figure 44: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 45: Latin America Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 46: Latin America Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 47: Latin America Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 48: Latin America Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031

Figure 49: Latin America Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031

Figure 50: Latin America Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031

Figure 51: Latin America Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 52: Latin America Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031

Figure 53: Latin America Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 54: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 55: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 56: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 57: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031

Figure 58: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031

Figure 59: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031

Figure 60: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 61: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031

Figure 62: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved